Sadzot-Delvaux, Catherine ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Virologie et immunologie - GIGA-M : Coordination scientifique
Sadzot-Delvaux C, Rentier B. Animal models of infection. In : Arvin AM, Gershon AA, eds. Varicella-Zoster virus : virology and clinical management. Cambridge : Publisher, 2000.
Ku CC, Besser J, Abendroth A, et al. Varicella-Zoster virus pathogenesis and immunobiology : new concepts emerging from investigations with the SCIDhu mouse model. J Virol 2005 ; 79 : 2651-8.
Cohen JI, Seidel KE. Generation of varicella-zoster virus (VZV) and viral mutants from cosmid DNAs : VZV thymidylate synthetase is not essential for replication in vitro. Proc Natl Acad Sci USA 1993 ; 90 : 7376-80.
Nagaike K, Mori Y, Gomi Y, et al. Cloning of the varicella-zoster virus genome as an infectious bacterial artificial chromosome in Escherichia coli. Vaccine 2004 ; 22 : 4069-74.
Fillet AM, Sadzot-Delvaux C, Rentier B. Virus varicelle zona. In : Huraux JM, Agut H, Nicolas JC, Peigue-Lafeuille H, eds. Traité de virologie médicale. Paris : Estem, 2003 : 179-93.
Muir WB, Nichols R, Breuer J. Phylogenetic analysis of varicella-zoster virus : evidence of intercontinental spread of genotypes and recombination. J Virol 2002 ; 76 : 1971-9.
Loparev VN, Gonzalez A, Deleon-Carnes M, et al. Global identification of three major genotypes of varicella-zoster virus : longitudinal clustering and strategies for genotyping. J Virol 2004 ; 78 : 8349-58.
Santos RA, Padilla JA, Hatfield C, Grose C. Antigenic variation of varicella zoster virus Fc receptor gE : loss of a major B cell epitope in the ectodomain. Virology 1998 ; 249 : 21-31.
Khoshnood B, Debruyne M, Lancon F, et al. Seroprevalence of varicella in the French population. Pediatr Infect Dis J 2006 ; 25 : 41-4.
Abendroth A, Morrow G, Cunningham AL, Slobedman B. Varicella-zoster virus infection of human dendritic cells and transmission to T cells : implications for virus dissemination in the host. J Virol 2001 ; 75 : 6183-92.
Ku CC, Padilla JA, Grose C, et al. Tropism of varicella-zoster virus for human tonsillar CD4 (+) T lymphocytes that express activation, memory, and skin homing markers. J Virol 2002 ; 76 : 11425-33.
Vossen MT, Biezeveld MH, de Jong MD, et al. Absence of circulating natural killer and primed CD8 + cells in life-threatening varicella. J Infect Dis 2005 ; 191 : 198-206.
Cole NL, Grose C. Membrane fusion mediated by herpesvirus glycoproteins : the paradigm of varicella-zoster virus. Rev Med Virol 2003 ; 13 : 207-22.
Defechereux P, Debrus S, Baudoux L, et al. Varicella-zoster virus open reading frame 4 encodes an immediate-early protein with posttranscriptional regulatory properties. J Virol 1997 ; 71 : 7073-9.
Forghani B, Mahalingam R, Vafai A, et al. Monoclonal antibody to immediate early protein encoded by varicella-zoster virus gene 62. Virus Res 1990 ; 16 : 195-210.
Debrus S, Sadzot-Delvaux C, Nikkels AF, et al. Varicella-zoster virus gene 63 encodes an immediate-early protein that is abundantly expressed during latency. J Virol 1995 ; 69 : 3240-5.
Bontems S, Di Valentin E, Baudoux L, et al. Phosphorylation of varicella-zoster virus IE63 protein by casein kinases influences its cellular localization and gene regulation activity. J Biol Chem 2002 ; 277 : 21050-60.
Habran L, Bontems S, Di Valentin E, et al. Varicella-zoster virus IE63 protein phosphorylation by roscovitine-sensitive cyclin-dependent kinases modulates its cellular localization and activity. J Biol Chem 2005 ; 280 : 29135-43.
Kenyon TK, Lynch J, Hay J, et al. Varicella-zoster virus ORF47 protein serine kinase : characterization of a cloned, biologically active phosphotransferase and two viral substrates, ORF62 and ORF63. J Virol 2001 ; 75 : 8854-8.
Lynch JM, Kenyon TK, Grose C, et al. Physical and functional interaction between the varicella zoster virus IE63 and IE62 proteins. Virology 2002 ; 302 : 71-82.
Di Valentin E, Bontems S, Habran L, et al. Varicella-zoster virus IE63 protein represses the basal transcription machinery by disorganizing the pre-initiation complex. Biol Chem 2005 ; 386 : 255-67.
Gilden DH, Cohrs RJ, Mahalingam R. Clinical and molecular pathogenesis of varicella virus infection. Viral Immunol 2003 ; 16 : 243-58.
Zerboni L, Ku CC, Jones CD, et al. Varicella-zoster virus infection of human dorsal root ganglia in vivo. Proc Natl Acad Sci USA 2005 ; 102 : 6490-5.
Mori I, Nishiyama Y. Herpes simplex virus and varicella-zoster virus : why do these human alphaherpesviruses behave so differently from one another? Rev Med Virol 2005 ; 15 : 393-406.
Cohen JI, Cox E, Pesnicak L, et al. The varicella-zoster virus open reading frame 63 latency-associated protein is critical for establishment of latency. J Virol 2004 ; 78 : 11833-40.
Sato H, Pesnicak L, Cohen JI. Use of a rodent model to show that varicella-zoster virus ORF61 is dispensable for establishment of latency. J Med Virol 2003 ; 70 : S79-S81.
Hood C, Cunningham AL, Slobedman B, et al. Varicella-zoster virus ORF63 inhibits apoptosis of primary human neurons. J Virol 2006 ; 80 : 1025-31.
Wang JP, Kurt-Jones EA, Shin OS, et al. Varicella-zoster virus activates inflammatory cytokines in human monocytes and macrophages via Toll-like receptor 2. J Virol 2005 ; 79 : 12658-66.
Hope-Simpson RE. The Nature of Herpes Zoster : A Long-Term Study and a New Hypothesis. Proc R Soc Med 1965 ; 58 : 9-20.
Morrow G, Slobedman B, Cunningham AL, Abendroth A. Varicella-zoster virus productively infects mature dendritic cells and alters their immune function. J Virol 2003 ; 77 : 4950-9.
Abendroth A, Lin I, Slobedman B, et al. Varicella-zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells. J Virol 2001 ; 75 : 4878-88.
Abendroth A, Slobedman B, Lee E, et al. Modulation of major histocompatibility class II protein expression by varicella-zoster virus. J Virol 2000 ; 74 : 1900-7.
Nikkels AF, Sadzot-Delvaux C, Pierard GE. Absence of intercellular adhesion molecule 1 expression in varicella zoster virus-infected keratinocytes during herpes zoster : another immune evasion strategy? Am J Dermatopathol 2004 ; 26 : 27-32.
Elion GB, Furman PA, Fyfe JA, et al. Selectivity of action of an anti-herpetic agent, 9- (2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 1977 ; 74 : 5716-20.
Whitley R. Treatment of Varicella. In : Arvin AM, Gershon AA, eds. Varicella-Zoster Virus : Virology and clinical managment. Cambridge : Cambridge University Press, 2000.
Derse D, Cheng YC, Furman PA, et al. Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9- (2-hydroxyethoxymethyl) guanine triphosphate. Effects on primer-template function. J Biol Chem 1981 ; 256 : 11447-51.
Gershon AA. Prevention and treatment of VZV infections in patients with HIV. Herpes 2001 ; 8 : 32-6.
Andrei G, De Clercq E, Snoeck R. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain) : differences between acyclovir and penciclovir? Antiviral Res 2004 ; 61 : 181-7.
Morfin F, Thouvenot D, De Turenne-Tessier M, Lina B, Aymard M, Ooka T. Phenotypic and genetic characterization of thymidine kinase from clinical strains of Varicella-zoster virus resistant to acyclovir. Antimicrob Agents Chemother 1999 ; 43 : 2412-6.
Chatis PA, Miller CH, Schrager LE, Crumpacker CS. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N Engl J Med 1989 ; 320 : 297-300.
Balfour Jr. HH, Benson C, Braun J, et al. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr 1994 ; 7 : 254-60.
De Clercq E. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochem Pharmacol 2004 ; 68 : 2301-15.
Sienaert R, Naesens L, Brancale A, et al. Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol Pharmacol 2002 ; 61 : 249-54.
Andrei G, Sienaert R, McGuigan C, et al. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides. Antimicrob Agents Chemother 2005 ; 49 : 1081-6.
Schang LM, Bantly A, Knockaert M, et al. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins. J Virol 2002 ; 76 : 7874-82.
Taylor SL, Kinchington PR, Brooks A, Moffat JF. Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus. J Virol 2004 ; 78 : 2853-62.
Takahashi M, Okuno Y, Otsuka T, et al. Development of a live attenuated varicella vaccine. Biken J 1975 ; 18 : 25-33.
Gomi Y, Sunamachi H, Mori Y, et al. Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J Virol 2002 ; 76 : 11447-59.
Grose C. Varicella vaccination of children in the United States : assessment after the first decade 1995-2005. J Clin Virol 2005 ; 33 : 89-95 ; (discussion 96-8).
Rentier B, Gershon AA. Consensus : varicella vaccination of healthy children-a challenge for Europe. Pediatr Infect Dis J 2004 ; 23 : 379-89.
Shinefield H, Black S, Digilio L, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J 2005 ; 24 : 665-9.
Knuf M, Habermehl P, Zepp F, et al. Immunogenicity and Safety of Two Doses of Tetravalent Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children. Pediatr Infect Dis J 2006 ; 25 : 12-8.
Jumaan AO, Yu O, Jackson LA, et al. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005 ; 191 : 2002-7.
Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005 ; 352 : 2271-84.
Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002 ; 287 : 606-11.
